2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. CDK
  5. CDK Inhibitor

CDK Inhibitor

CDK Isoform Comparison

CDK Inhibitors (713):

Cat. No. Product Name Effect Purity
  • HY-50767R
    Palbociclib (Standard)
    		Inhibitor
    Palbociclib (Standard) is the analytical standard of Palbociclib. This product is intended for research and analytical applications. Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma.
  • HY-W654305
    Palbociclib-d4
    		Inhibitor
    Palbociclib-d4 is deuterium labeled Palbociclib. Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma.
  • HY-169670
    Protein kinase inhibitor 13
    		Inhibitor
    Protein kinase inhibitor 13 (Compound I-90) is the inhibitor for protein kinase that exhibits inhibitory effects on kinases such as PIM-1, CDK-2, GSK-3 and SRC.
  • HY-157647
    1-Stearoyl-2-Adrenoyl-sn-glycero-3-PC
    		Inhibitor
    1-Stearoyl-2-Adrenoyl-sn-glycero-3-PC (PC(18:0/22:4)) is an inhibitor of cyclin-dependent kinases (CDKs).? 1-Stearoyl-2-Adrenoyl-sn-glycero-3-PC induces apoptosis and inhibits the growth of various cancer cell lines.
  • HY-101467AR
    Trilaciclib (hydrochloride) (Standard)
    		Inhibitor
    Trilaciclib (hydrochloride) (Standard) is the analytical standard of Trilaciclib (hydrochloride). This product is intended for research and analytical applications. Trilaciclib hydrochloride (G1T28 hydrochloride) is a CDK4/6 inhibitor with IC50s of 1 nM and 4 nM for CDK4 and CDK6, respectively.
  • HY-147131
    CDK9-IN-30
    		Inhibitor ≥98.0%
    CDK9-IN-30 is a CDK9 inhibitor that inhibits HIV-1 viral replication.
  • HY-169683
    CDK2-IN-39
    		Inhibitor
    CDK2-IN-39 (compound 4) is a CDK2 inhibitor.
  • HY-128669R
    Abemaciclib metabolite M2 (Standard)
    		Inhibitor
  • HY-121174
    Alaternin
    		Inhibitor
    Alaternin (Catharticin) is an anthraquinone compound with antioxidant and hepatoprotective activities. Alaternin has an inhibitory activity against hydroxyl radicals generated in a cell-free chemical system (FeSO4/H2O2) with an IC50 value of 3.05 μM. Alaternin exhibits hepatoprotective activity against Tacrine (HY-111338)-induced toxicity in human hepatic HepG2 cells with an EC50 value of 4.02 μM.
  • HY-172245
    Zeltociclib
    		Inhibitor
    Zeltociclib is a cyclin-dependent kinase inhibitor with antitumor effects.
  • HY-111260
    R547 mesylate
    		Inhibitor
    R547 mesylate is a potent, selective and orally active ATP-competitive CDK inhibitor, with Kis of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively.
  • HY-112403
    (S)-Roscovitine
    		Inhibitor
    (S)-Roscovitine ((S)-Seliciclib; (S)-CYC202) is a potent and cross the blood-brain barrier CDKs inhibitor. (S)-Roscovitine shows neuroprotective efficacy. (S)-Roscovitine has the potential for the research of stroke.
  • HY-W050154R
    Kojic acid (Standard)
    		Inhibitor
    Kojic acid (Standard) is the analytical standard of Kojic acid. This product is intended for research and analytical applications. Kojic acid is a substance produced by Aspergillus oryzae, with various biological activities including antitumor, insecticidal, antibacterial, antioxidant, and radioprotective effects. Kojic acid exhibits tyrosinase inhibition activity by capturing copper ions that bind to the active site of tyrosinase, preventing its activation. Tyrosinase is a key enzyme in the biosynthesis of melanin, so kojic acid can block melanin production. Additionally, kojic acid shows potential inhibition of NF-κB activity in human keratinocytes, which may also be related to the anti-melanogenic effect induced by kojic acid. Kojic acid is effective when administered orally and can also be absorbed transdermally. Nano-carrier systems prepared with kojic acid demonstrate effective delivery of anticancer drugs. Kojic acid holds promise for research in cancer, infectious diseases, and skin whitening among other fields.